VariZIG Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The varizig market research report is one of a series of new reports that provides varizig market statistics, including varizig industry global market size, regional shares, competitors with a varizig market share, detailed varizig market segments, market trends and opportunities, and any further data you may need to thrive in the varizig industry. This varizig market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing incidence of chickenpox, rising investments in the development of varicella-related biologics, growing demand for immune globulin products, increasing public health initiatives, and rising clinical trials. Major trends in the forecast period include technological advancements, adoption in global humanitarian, advancements in recombinant DNA technology, development of novel formulations, and telemedicine.

The increasing incidence of varicella-zoster virus (VZV) infections is expected to drive the growth of the varizig market. VZV is a highly contagious virus that initially causes chickenpox and can later reactivate to cause shingles (herpes zoster). The rise in VZV infections, leading to conditions such as chickenpox and shingles, can be attributed to factors such as lower vaccination rates, an aging population, and immune suppression due to medical treatments. Varizig is beneficial for patients affected by the virus, as it provides passive immunity, helping to reduce the severity and duration of chickenpox symptoms. It also prevents complications in high-risk groups, such as immunocompromised patients, and offers protection for neonates and pregnant women exposed to the virus. For example, in November 2024, the Florida Department of Health reported an increase in varicella cases to 653 in 2023, up from 428 cases in 2022. Thus, the rising incidence of varicella-zoster infections is driving the demand for varizig.

The growth of the varizig market is also expected to be driven by the rise in healthcare spending. Healthcare spending refers to the total expenditure on medical services, including care, hospital services, medications, research, and infrastructure, to improve the health and well-being of individuals and populations. This increase in spending is fueled by factors such as an aging population, advances in medical technology, the rising prevalence of chronic diseases, and growing healthcare demands. Higher healthcare expenditure enables the acquisition and distribution of vital treatments such as Varizig, ensuring its availability for high-risk populations. It also supports timely treatment for varicella-zoster virus infections and helps reduce the overall healthcare burden from complications associated with the virus. For instance, according to the Office for National Statistics, healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to a 0.9% increase in 2022. In 2023, UK healthcare expenditure totaled around $317.63 billion (£292 billion), further driving the demand for varizig.

A significant trend in the varizig market is the formation of strategic supply agreements to expand the product’s availability and meet the growing demand for passive immunization, particularly in high-risk and emergency situations. These agreements set out terms for the delivery of goods or services, including pricing and schedules. For example, in July 2022, Kamada Ltd., an Israeli biopharmaceutical company, announced an $11.4 million procurement agreement to supply Varizig to an undisclosed international organization primarily operating in Latin America. This agreement, set to deliver supplies from late 2022 through mid-2023, is part of Kamada’s strategy to expand its sales of FDA-approved plasma-derived therapies into international markets, particularly beyond North America. Varizig is specifically indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk groups, such as immunocompromised patients and newborns, making it a critical treatment option for these vulnerable populations.

The key company operating in the varizig market is Emergent BioSolutions Inc.

North America was the largest region in the varizig market in 2024. The regions covered in varizig report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the varizig market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

VariZIG is a hyperimmune globulin derived from human plasma, enriched with high levels of antibodies against the varicella-zoster virus (VZV). It is used as a post-exposure prophylaxis to reduce the severity of chickenpox in high-risk individuals, including immunocompromised patients, pregnant women, and newborns. Administered intramuscularly, VariZIG provides passive immunity by delivering pre-formed antibodies. It is most effective when given within 96 hours of exposure to VZV.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary patient conditions for varizig include immunocompromised individuals and pregnant women. Immunocompromised patients have weakened immune systems due to conditions such as HIV, cancer treatments, or immunosuppressive therapy. VariZIG is distributed through various channels, including hospitals, pharmacies, and healthcare providers. It is used by a range of end-users, including adults, geriatric patients, and pediatric populations.

The varizig market consists of sales of pre-filled syringes, injectable solutions, and single-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.